precisionmedicineonline7h
FDA Approves Autolus' CAR T-Cell Therapy Aucatzyl for B-Cell Acute Lymphoblastic Leukemia
The agency reviewed data from the FELIX trial, in which 63 percent of patients achieved a complete remission on the cell therapy at any time point.
precisionmedicineonline9h
Arcus Confident in Anti-TIGIT, Immunotherapy, Chemo Regimen After Seeing Phase II Survival Data
The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.
precisionmedicineonline11h
Xenetic Biosciences Extends Drug Development Pact With Scripps Research Institute
The partners are advancing a pipeline of engineered DNase I therapies designed to work with CAR T cells to kill tumor cells.
precisionmedicineonline13h
Rocket Pharma Starts Rolling BLA Submission for Fanconi Anemia Gene Therapy
RP-L102, which the firm designed to treat a form of disease caused by FANCA mutations, is already under review with the European Medicines Agency.